Şengül Çağlayan

18PUBLICATIONS
72CO-AUTHORS
Infant and child healthDisease surveillanceAboriginal and Torres Strait Islander youth and family social and emotional wellbeingCancer therapy (excl. chemotherapy and radiation therapy)Autoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Feb 21, 2026
Real-world efficacy, safety, and drug retention of anakinra and canakinumab in paediatric colchicine-resistant familial Mediterranean fever: Insights from a single-centre cohort.

Şengül Çağlayan, Taner Coşkuner, Kadir Ulu

|Aug 01, 2025
Three-year follow-up of canakinumab dose extension in children with colchicine-resistant familial Mediterranean fever: PeRA-RG Experience.

Gülşah Kavrul Kayaalp, Şengül Çağlayan, Kadir Ulu

|Aug 01, 2024
Real-life data of etanercept efficacy and safety in juvenile idiopathic arthritis: a 24-month retrospective study at a single center.

Ramazan Emre Yiğit, Kadir Ulu, Şengül Çağlayan

|Jun 27, 2024
The cultural differences in transition assessment: Evaluation of TRANSITION-Q and STARx scales on Turkish rheumatic patients.

Ramazan Emre Yiğit, Şengül Çağlayan, Betül Sözeri

|Nov 24, 2023
Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience.

Gülşah Kavrul Kayaalp, Şengül Çağlayan, Fatma Gül Demirkan

|Nov 16, 2023
The safety of canakinumab in systemic juvenile idiopathic arthritis and autoinflammatory diseases in pediatric patients: a multicenter study.

Taner Coşkuner, Şengül Çağlayan, Özlem Akgün

Pageof 3

Frequent Collaborators

17 joint publications

Betül Sözeri

9 joint publications

Kadir Ulu

9 joint publications

Mustafa Çakan

8 joint publications

Nuray Aktay Ayaz